Fiche personne
Territoire
Franche-Comté
Statut
Hospitalier
Équipes/plateformes
Recherche
Expertises :
- Clinique:Pharmacologie
Publications
Plasma clearance of 5-fluorouracil is more influenced by variations in glomerular filtration rate than by uracil concentration.
Matheux A, Collas L, Grisard M, Goulaieff L, Ghiringhelli F, Bengrine-Lefevre L, Vincent J, Goirand F, Royer B, Schmitt A
Cancer Chemother Pharmacol. 2024 12 19;95(1):9
Large-Scale DPD Testing Should Be More Than an Option.
Etienne-Grimaldi MC, Royer B, Launay M, Schmitt A, Thomas F, Ciccolini J,
JCO Oncol Pract. 2024 12 3;:OP2400464
The EMMY longitudinal, cohort study: real-world data to describe multiple myeloma management and outcomes as more therapeutic options emerge.
Decaux O, Garlantézec R, Belhadj-Merzoug K, Macro M, Frenzel L, Perrot A, Moreau P, Royer B, Caillot D, Leleu X, Mohty M, Karlin L, Feugier P, Rigaudeau S, Fontan J, Sonntag C, Vincent L, Chalopin T, Avet Loiseau H, Maarouf Z, Chanaz L, Texier N, Hulin C
Clin Hematol Int. 2024 07 23;6(3):22-27
Improving olaparib exposure to optimize adverse effects management.
Sterlé M, Puszkiel A, Burlot C, Pereira E, Bellesoeur A, De Percin S, Beinse G, Fumet JD, Favier L, Niogret J, Blanchet B, Royer B, Bengrine-Lefevre L, Schmitt A
Ther Adv Med Oncol. 2024 04 24;16:17588359241248328
Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency.
Schmitt A, Royer B, Boidot R, Berthier J, Ghiringhelli F
Front Oncol. 2023 06 20;13:1187052
Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping.
Royer B, Launay M, Ciccolini J, Derain L, Parant F, Thomas F, Guitton J
ESMO Open. 2023 05 31;8(3):101577
Pharmacokinetics and Pharmacodynamic of Alpelisib.
Royer B, Kaderbhaï CG, Schmitt A
Clin Pharmacokinet. 2023 01 12;:
Renal impairment and abnormal liver function tests in pre-therapeutic phenotype-based DPD deficiency screening using uracilemia: a comprehensive population-based study in 1138 patients.
Callon S, Brugel M, Botsen D, Royer B, Slimano F, Feliu C, Gozalo C, Konecki C, Devie B, Carlier C, Daire V, Laurés N, Perrier M, Djerada Z, Bouché O
Ther Adv Med Oncol. 2023 01 10;15:17588359221148536
Assessment of overranging as a function of pitch, collimation and rotation time for three of the most recent and widespread ct scans in France.
González-Méndez LA, Bozec J, Rousselle I, Royer B, Noel A, Farah J
Radiat Prot Dosimetry. 2022 12 14;:
Plasma Uracil as a DPD Phenotyping Test: Pre-Analytical Handling Matters!
Thomas F, Launay M, Guitton J, Loriot MA, Boyer JC, Haufroid V, Etienne-Grimaldi MC, Royer B,
Clin Pharmacol Ther. 2022 11 22;:
Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency.
Maillard M, Launay M, Royer B, Guitton J, Gautier-Veyret E, Broutin S, Tron C, Le Louedec F, Ciccolini J, Richard D, Alarcan H, Haufroid V, Tafzi N, Schmitt A, Etienne-Grimaldi MC, Narjoz C, Thomas F,
Br J Clin Pharmacol. 2022 09 14;:
Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 Patients.
Paquette B, Kalbacher E, Mercier F, Lakkis Z, Doussot A, Turco C, Caputo E, Pili-Floury S, Royer B, Mansi L, Delroeux D, Demarchi M, Pivot X, Chauffert B, Clement E, Heyd B
Ann Surg Oncol. 2022 Jan 7;:
Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients.
Marouille AL, Petit E, Kaderbhaï C, Desmoulins I, Hennequin A, Mayeur D, Fumet JD, Ladoire S, Tharin Z, Ayati S, Ilie S, Royer B, Schmitt A
Pharmaceutics. 2021 Oct 16;13(10):
Population Pharmacokinetics of Palbociclib in aReal-World Situation.
Royer B, Kaderbhaï C, Fumet JD, Hennequin A, Desmoulins I, Ladoire S, Ayati S, Mayeur D, Ilie S, Schmitt A
Pharmaceuticals (Basel). 2021 Feb 24;14(3):
Validation of an HPLC-MS/MS Method for the Determination of Plasma Ticagrelor and Its Active Metabolite Useful for Research and Clinical Practice.
Lagoutte-Renosi J, Royer B, Rabani V, Davani S
Molecules. 2021 Jan 8;26(2):
Population pharmacokinetic and pharmacodynamic modeling of capecitabine and its metabolites in breast cancer patients.
Lunar N, Etienne-Grimaldi MC, Macaire P, Thomas F, Dalenc F, Ferrero JM, Pivot X, Milano G, Royer B, Schmitt A
Cancer Chemother Pharmacol. 2021 Jan 2;:
Association of 5-FU Therapeutic Drug Monitoring to DPD Phenotype Assessment May Reduce 5-FU Under-Exposure.
Dolat M, Macaire P, Goirand F, Vincent J, Hennequin A, Palmier R, Bengrine-Lefevre L, Ghiringhelli F, Royer B, Schmitt A
Pharmaceuticals (Basel). 2020 Nov 23;13(11):
Exposure-Response Analysis of Raltitrexed Assessing Liver Toxicity.
Royer B, Schmitt A, Nguyen T, Paillard MJ, Jary M, Demarchi M, Vernerey D, Henriques J, Jacquin M, Borg C, Kim S
Br J Clin Pharmacol. 2020 Aug 12;:
Systemic high-dose intravenous methotrexate in patients with central nervous system metastatic breast cancer.
Bazan F, Dobi E, Royer B, Curtit E, Mansi L, Menneveau N, Paillard MJ, Meynard G, Villanueva C, Pivot X, Chaigneau L
BMC Cancer. 2019 Nov 1;19(1):1029
A simple and fast LC-MS/MS method for the routine measurement of cabozantinib, olaparib, palbociclib, pazopanib, sorafenib, sunitinib and its main active metabolite in human plasma.
Jolibois J, Schmitt A, Royer B
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.. 2019 Oct 21;1132:121844
A 1-Year Prospective French Nationwide Study of Emergency Hospital Admissions in Children and Adults with Primary Immunodeficiency.
Coignard-Biehler H, Mahlaoui N, Pilmis B, Barlogis V, Brosselin P, De Vergnes N, Debré M, Malphettes M, Frange P, Catherinot E, Pellier I, Durieu I, Perlat A, Royer B, Le Quellec A, Jeziorski E, Fischer A, Lortholary O, ,Aaron L, Adoue D, Aguilar C, Aladjidi N, Alcais A, Amoura Z, Arlet P, Armari-Alla C, Bader-Meunier B, Bayart S, Bertrand Y, Bienvenu B, Blanche S, Bodet D, Bonnotte B, Borie R, Boutard P, Briandet C, Brion JP, Brouard J, Cohen-Beaussant S, Costes L, Couderc LJ, Cougoul P, Courteille V, de Saint Basile G, Devoldere C, Deville A, Donadieu J, Dore E, Dulieu F, Edan C, Entz-Werle N, Fieschi C, Forestier A, Fouyssac F, Gajdos V, Galicier L, Gandemer V, Gardembas M, Gaud C, Guillerm G, Hachulla E, Hamidou M, Hermine O, Hoarau C, Humbert S, Jaccard A, Jacquot S, Jais JP, Jaussaud R, Jeandel PY, Kebaili K, Korganow AS, Lambotte O, Lanternier F, Larroche C, Lascaux AS, Le Moigne E, Le Moing V, Lebranchu Y, Lecuit M, Lefevre G, Lemal R, Te VLT, Marie-Cardine A, Silva NM, Masseau A, Massot C, Mazingue F, Merlin E, Michel G, Millot F, Monlibert B, Monpoux F, Moshous D, Mouthon L, Munzer M, Neven B, Nove-Josserand R, Oksenhendler E, Ouachée-Chardin M, Oudot C, Pagnier A, Pasquali JL, Pasquet M, Perel Y, Picard C, Piguet C, Plantaz D, Provot J, Quartier P, Rieux-Laucat F, Roblot P, Roger PM, Rohrlich PS, Rubie H, Salle V, Sarrot-Reynauld F, Servettaz A, Stephan JL, Schleinitz N, Suarez F, Swiader L, Taque S, Thomas C, Tournilhac O, Thumerelle C, Tron F, Vannier JP, Viallard JF
J. Clin. Immunol.. 2019 Aug 10;:
CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin.
Galaine J, Turco C, Vauchy C, Royer B, Mercier-Letondal P, Queiroz L, Loyon R, Mouget V, Boidot R, Laheurte C, Lakkis Z, Jary M, Adotévi O, Borg C, Godet Y
Int. J. Cancer. 2019 Aug 9;:
Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study.
Jouinot A, Royer B, Chatelut E, Moeung S, Assié G, Thomas-Schoemann A, Bertherat J, Goldwasser F, Blanchet B
Endocr Connect. 2018 Dec 1;7(12):1409-1414
Personalized identification of tumor-associated immunogenic neoepitopes in hepatocellular carcinoma in complete remission after sorafenib treatment.
Vrecko S, Guenat D, Mercier-Letondal P, Faucheu H, Dosset M, Royer B, Galaine J, Boidot R, Kim S, Jary M, Adotévi O, Borg C, Godet Y
Oncotarget. 2018 Oct 23;9(83):35394-35407
Pharmacokinetic drug-drug interaction between mitotane and etoposide in the treatment of adrenocortical carcinoma.
Jouinot A, Royer B, Moeung S, Chatelut E, Bellesoeur A, Assié G, Thomas-Schoemann A, Bertherat J, Goldwasser F, Blanchet B
Ann. Oncol.. 2018 Oct;29 Suppl 8:viii149
[Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA, Ciccolini J, Thomas F, Barin-Le-Guellec C, Royer B, Milano G, Picard N, Becquemont L, Verstuyft C, Narjoz C, Schmitt A, Bobin-Dubigeon C, Harle A, Paci A, Poinsignon V, Quaranta S, Evrard A, Hennart B, Broly F, Fonrose X, Lafay-Chebassier C, Wozny AS, Masskouri F, Boyer JC, Etienne-Grimaldi MC
Bull Cancer. 2018 Apr;105(4):397-407
Long-term follow-up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia.
Feugier P, Aurran T, Mahé B, Letestu R, Nguyen-Khac F, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delépine R, Vaudaux S, Van den Neste E, Béné MC, Cymbalista F, Roosweil D, Leprêtre S
Haematologica. 2018 Mar 15;:
A new anti-mesothelin antibody targets selectively the membrane-associated form.
Asgarov K, Balland J, Tirole C, Bouard A, Mougey V, Ramos D, Barroso A, Zangiacomi V, Jary M, Kim S, Gonzalez-Pajuelo M, Royer B, de Haard H, Clark A, Wijdenes J, Borg C
MAbs. 2017 Apr;9(3):567-577
Hemodialysis does not impact axitinib exposure: clinical case of a patient with metastatic renal cell carcinoma.
Thiery-Vuillemin A, Orillard E, Mouillet G, Calcagno F, Devillard N, Bouchet S, Royer B
Cancer Chemother. Pharmacol.. 2017 Apr;:
Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: The multiparametric approach is not convincing.
Etienne-Grimaldi MC, Le Guellec CB, Boyer JC, Chatelut E, Evrard A, Loriot MA, Paci A, Royer B, Thomas F, Ciccolini J
Semin. Oncol.. 2017 Apr;44(2):159-160
Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity.
Beziaud L, Mansi L, Ravel P, Marie-Joseph EL, Laheurte C, Rangan L, Bonnefoy F, Pallandre JR, Boullerot L, Gamonet C, Vrecko S, Queiroz L, Maurina T, Mouillet G, Hon TN, Curtit E, Royer B, Gaugler B, Bayry J, Tartour E, Thiery-Vuillemin A, Pivot X, Borg C, Godet Y, Adotévi O
Cancer Res.. 2016 Jul;76(14):4100-12
Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS).
Quinquenel A, Willekens C, Dupuis J, Royer B, Ysebaert L, De Guibert S, Michallet AS, Feugier P, Guieze R, Levy V, Delmer A
Am J Hematol. 2015 Mar;90(3):204-7
In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
Angelot-Delettre F, Roggy A, Frankel AE, Lamarthee B, Seilles E, Biichle S, Royer B, Deconinck E, Rowinsky EK, Brooks C, Bardet V, Benet B, Bennani H, Benseddik Z, Debliquis A, Lusina D, Roussel M, Solly F, Ticchioni M, Saas P, Garnache-Ottou F
Haematologica. 2015 Feb;100(2):223-30
Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma.
Thiery-Vuillemin A, Mouillet G, Nguyen Tan Hon T, Montcuquet P, Maurina T, Almotlak H, Stein U, Montange D, Foubert A, Nerich V, Pivot X, Royer B
Cancer Chemother Pharmacol. 2014 May;73(5):999-1007
Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma.
Thiery-Vuillemin A, Laheurte C, Mansi L, Royer B, Pivot X, Borg C, Adotevi O
J Immunother. 2014 Jan;37(1):51-4
Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer.
Thiery-Vuillemin A, Curtit E, Maurina T, Montange D, Succi C, Nguyen T, Kim S, Montcuquet P, Pivot X, Royer B
Ann Oncol. 2012 Nov;23(11):2992-3
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial.
Lepretre S, Aurran T, Mahe B, Cazin B, Tournilhac O, Maisonneuve H, Casasnovas O, Delmer A, Leblond V, Royer B, Corront B, Chevret S, Delepine R, Vaudaux S, Van Den Neste E, Bene MC, Letestu R, Cymbalista F, Feugier P
Blood. 2012 May 31;119(22):5104-10
Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program.
Damaj G, Malard F, Hulin C, Caillot D, Garidi R, Royer B, Marit G, Stoppa AM, Banos A, Morineau N, Moreau P, Fitoussi O, Tiab M, Moreau P
Leuk Lymphoma. 2012 Apr;53(4):632-4
High-pressure intrapleural chemotherapy: feasibility in the pig model.
Facy O, Pages PB, Ortega-Deballon P, Magnin G, Ladoire S, Royer B, Chauffert B, Bernard A
World J Surg Oncol. 2012 Feb 6;10:29.
Intraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic study.
Royer B, Kalbacher E, Onteniente S, Jullien V, Montange D, Piedoux S, Thiery-Vuillemin A, Delroeux D, Pili-Floury S, Guardiola E, Combe M, Muret P, Nerich V, Heyd B, Chauffert B, Kantelip JP, Pivot X
Br J Cancer. 2012 Jan 31;106(3):460-7
Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial.
Braun T, Itzykson R, Renneville A, de Renzis B, Dreyfus F, Laribi K, Bouabdallah K, Vey N, Toma A, Recher C, Royer B, Joly B, Vekhoff A, Lafon I, Sanhes L, Meurice G, Orear C, Preudhomme C, Gardin C, Ades L, Fontenay M, Fenaux P, Droin N, Solary E
Blood. 2011 Oct 6;118(14):3824-31
Impact of sunitinib pharmacokinetic monitoring in a patient with metastatic renal cell carcinoma undergoing hemodialysis.
Thiery-Vuillemin A, Montange D, Kalbacher E, Maurina T, Nguyen T, Royer B, Bouchet S, Bazan F, Curtit E, Pivot X
Ann Oncol. 2011 Sep;22(9):2152-4.
Level of evidence for therapeutic drug monitoring of taxanes.
Gerritsen-van Schieveen P, Royer B
Fundam Clin Pharmacol. 2011 Aug;25(4):414-24
Level of evidence for therapeutic drug monitoring for etoposide after oral administration.
Gerritsen-van Schieveen P, Royer B
Fundam Clin Pharmacol. 2011 Jun;25(3):277-82
Protective effect of intra-peritoneal epinephrine on postoperative renal function after cisplatin-based intra-peritoneal intra-operative chemotherapy.
Pili-Floury S, Royer B, Bartholin F, Crumiere N, Combe M, Chalopin JM, Pivot X, Heyd B, Chauffert B, Samain E
Eur. J. Obstet. Gynecol. Reprod. Biol.. 2011 Jun;156(2):199-203
Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C.
Piedoux S, Monnet E, Piroth L, Montange D, Royer B, Thevenot T, Kantelip JP, Di Martino V, Muret P
Antivir Ther. 2011;16(8):1317-26.
[Level of evidence for therapeutic drug monitoring of everolimus].
Goirand F, Royer B, Hulin A, Saint-Marcoux F
Therapie. 2011 Jan-Feb;66(1):57-61
[Level of evidence for therapeutic drug monitoring of MPA in hematopoietic stem cell transplantation].
Gerritsen-van Schieveen P, Royer B
Therapie. 2011 Jan-Feb;66(1):51-5
Duration: escalation study of oral etoposide with carboplatin in patients with varied solid tumors.
Thiery-Vuillemin A, Dobi E, Nguyen T, Royer B, Montange D, Maurina T, Kalbacher E, Bazan F, Villanueva C, Demarchi M, Chaigneau L, Ivanaj A, Pivot X
Anticancer Drugs. 2010 Nov;21(10):958-62.
An APCI LC-MS/MS method for routine determination of capecitabine and its metabolites in human plasma.
Montange D, Berard M, Demarchi M, Muret P, Piedoux S, Kantelip JP, Royer B
J Mass Spectrom. 2010 Jun;45(6):670-7.
[Level of evidence for therapeutic drug monitoring for docetaxel].
Gerritsen-van Schieveen P, Royer B
Therapie. 2010 May-Jun;65(3):201-6
[Level of evidence for therapeutic drug monitoring for etoposide after oral administration].
Schieveen PG, Hulin A, Muret P, Royer B
Therapie. 2010 May-Jun;65(3):207-12
[Level of evidence for therapeutic drug monitoring for paclitaxel].
Gerritsen-van Schieveen P, Royer B
Therapie. 2010 May-Jun;65(3):195-200
[Level of evidence for therapeutic drug monitoring of carboplatin].
Hulin A, Chatelut E, Royer B, Le Guellec C
Therapie. 2010 May-Jun;65(3):157-62
[Level of evidence for therapeutic drug monitoring of cisplatin].
Hulin A, Royer B, Chatelut E, Le Guellec C
Therapie. 2010 May-Jun;65(3):151-5
[Therapeutic drug monitoring of tyrosine-kinase inhibitors in the treatment of chronic myelogenous leukaemia: interests and limits].
Bouchet S, Royer B, Le Guellec C, Titier K
Therapie. 2010 May-Jun;65(3):213-8
Intraoperative chemotherapy with cisplatin and epinephrine after cytoreductive surgery in patients with recurrent ovarian cancer: a phase I study.
Guardiola E, Chauffert B, Delroeux D, Royer B, Heyd B, Combe M, Benoit L, Causeret S, Demarchi M, Magnin G, Mayer F, Tixier H, Pivot X
Anticancer Drugs. 2010 Mar;21(3):320-5.
Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer.
Royer B, Yin W, Pegram M, Ibrahim N, Villanueva C, Mir D, Erlandsson F, Pivot X
Br J Cancer. 2010 Mar 2;102(5):827-32
Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM).
Roussel M, Moreau P, Huynh A, Mary JY, Danho C, Caillot D, Hulin C, Fruchart C, Marit G, Pegourie B, Lenain P, Araujo C, Kolb B, Randriamalala E, Royer B, Stoppa AM, Dib M, Dorvaux V, Garderet L, Mathiot C, Avet-Loiseau H, Harousseau JL, Attal M
Blood. 2010 Jan 7;115(1):32-7
Pharmacokinetics of mycophenolic acid administered 3 times daily after hematopoietic stem cell transplantation with reduced-intensity regimen.
Royer B, Larosa F, Legrand F, Gerritsen-van Schieveen P, Berard M, Kantelip JP, Deconinck E
Biol Blood Marrow Transplant. 2009 Sep;15(9):1134-9
Intra-operative intra-peritoneal chemotherapy with cisplatin in patients with peritoneal carcinomatosis of ovarian cancer.
Guardiola E, Delroeux D, Heyd B, Combe M, Lorgis V, Demarchi M, Stein U, Royer B, Chauffert B, Pivot X
World J Surg Oncol. 2009 Feb 9;7:14.
Pharmacokinetic modelling and development of Bayesian estimators for therapeutic drug monitoring of mycophenolate mofetil in reduced-intensity haematopoietic stem cell transplantation.
Saint-Marcoux F, Royer B, Debord J, Larosa F, Legrand F, Deconinck E, Kantelip JP, Marquet P
Clin Pharmacokinet. 2009;48(10):667-75
Population Pharmacokinetics and Dosing Recommendations for Cisplatin during Intraperitoneal Peroperative Administration Development of a Limited Sampling Strategy for Toxicity Risk Assessment
Royer B, Jullien V, Guardiola E, Heyd B, Chauffert B, Kantelip JP, Pivot X
Clin Pharmacokinet. 2009;48(3):169-80
Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study.
Chaigneau L, Royer B, Montange D, Nguyen T, Maurina T, Villanueva C, Demarchi M, Borg C, Fagnoni-Legat C, Kantelip JP, Pivot X
Ann Oncol. 2008 Nov;19(11):1980-1.
Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
Royer B, Delroeux D, Guardiola E, Combe M, Hoizey G, Montange D, Kantelip JP, Chauffert B, Heyd B, Pivot X
Cancer Chemother Pharmacol. 2008 Mar;61(3):415-21
Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
Molucon-Chabrot C, Isambert N, Benoit L, Zanetta S, Fraisse J, Guilland JC, Royer B, Monin-Baroille P, Flesch M, Fargeot P, Coudert B, Mayer F, Fumoleau P, Chauffert B
Anticancer Drugs. 2006 Nov;17(10):1211-7.
High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia.
Rea D, Legros L, Raffoux E, Thomas X, Turlure P, Maury S, Dupriez B, Pigneux A, Choufi B, Reman O, Stephane D, Royer B, Vigier M, Ojeda-Uribe M, Recher C, Dombret H, Huguet F, Rousselot P
Leukemia. 2006 Mar;20(3):400-3.
Delayed 24 hours N-omega-nitro-(L)-arginine methyl ester injection induces pharmacological cardioprotection against reperfusion injury.
Davani S, Vergely C, Royer B, Bouhaddi M, Reyssie H, Rochette L, Kantelip J
Cell Mol Biol. 2006;52 Suppl. S:868-73.
Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding.
Royer B, Guardiola E, Polycarpe E, Hoizey G, Delroeux D, Combe M, Chaigneau L, Samain E, Chauffert B, Heyd B, Kantelip JP, Pivot X
Anticancer Drugs. 2005 Oct;16(9):1009-16.
